Halozyme Announces Roche Marketing Authorization For MabThera SC For ... MarketWatch SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera ® (rituximab) for the treatment of ... |
